On April 19, 2022, Tessera Therapeutics, Inc. closed the transaction. The company has received more than $300,000,000 in the transaction. The transaction included participation from existing investors Alaska Permanent Fund, Altitude Life Science Ventures, new investors a wholly-owned subsidiary of the Abu Dhabi Investment Authority, ARTIS Ventures, Cormorant Asset Management, LP, Flagship Pioneering, Hanwha General Chemical USA Corp., Longevity Vision Fund, a fund managed by Longevity Vision Investment Advisors, LLC, SALT Fund I, L.P., a fund managed by SALT Venture Group, LLC, existing investor SoftBank Vision Fund 2, a fund managed by existing investor SoftBank Investment Advisers (UK) Limited, T. Rowe Price Group, Inc., March Capital Venture Management Services, LLC, the company's founder and others including company's existing investors.